ro sparks glp 1 Offers Eli Lilly's Foundayo™, the Newest GLP-1 Innovation Ro launches the GLP-1 Insurance
Description
Thirty-one percent of employers currently covering GLP-1 drugs for weight loss are either considering stopping coverage or unsure whether they will continue over the next twelve to twenty-four months
The BBB page shows mixed customer feedback, including at least one review titled with zero stars
Even then, the mixed effects analyses did not reveal a significant durability of weight loss with longer durations of therapy
Louis Bariatrics, we discuss both options together, not as competing paths
But outcomes vary by individual
In T2DM: 0.49% after 13 hr, n=205
